ZTS Q4 2024 Earnings — Zoetis Inc. Revenue & Financial Results | Market Cap Arena

ZTSZoetis Inc.

$54B

Q4 2024 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$2.3B+4.7% YoY

Gross Profit

$1.6B68.0% margin

Operating Income

$765M33.0% margin

Net Income

$581M25.1% margin

EPS (Diluted)

$1.29

QoQ Revenue Growth

-3.0%

Cash Flow

Operating Cash Flow

$905M

Free Cash Flow

$689M

Stock-Based Comp.

$19M

Balance Sheet

Total Assets

$14.2B

Total Liabilities

$9.5B

Stockholders' Equity

$4.8B

Cash & Equivalents

$2.0B

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$2.3B	$2.2B	+4.7%
Gross Profit	$1.6B	$1.4B	+8.8%
Operating Income	$765M	$709M	+7.9%
Net Income	$581M	$525M	+10.7%

Revenue Segments

Horses

$5.8B89%

Cattle

$399M6%

Swine

$128M2%

Poultry

$117M2%

Fish

$65M1%

Geographic Segments

United States Segment

$1.3B55%

International Segment

$1.0B45%